Excitement Shown With CDK4/6 Inhibitors and More in Breast Cancer Research

Seth Wander, MD, PhD, Massachusetts General Hospital, discusses what research and topics excite him when evaluating future treatments for patients with breast cancer.

In his own research, Wander is focused on examining CDK4/6 inhibition for patients with hormone receptor-positive metastatic breast cancer (MBC) with ESR1 mutations and fusions. During a presentation at the 2022 American Association for Cancer Research Annual Meeting, research was presented by Jamie Brett, fellow at Dana-Farber/Mass General Brigham Hematology/Oncology program, discussed findings from a study which evaluated patients with MBC who had used a CDK4/6 inhibitor within 30 days of circulating tumor (ct)DNA testing. Then, patients were analyzed for time-to-next-treatment to evaluate the CDK4/6 inhibitors. What they found was that treatment CDK4/6 inhibitors proved to be effective in this patient population.

Moving forward within the breast cancer space, experts including Wander look forward to seeing more novel agents come into play and seeing the different ways that they can be used, including CDK inhibitors, antiestrogens, antibody drug conjugates, and more.

Transcription:

0:08 | We're starting to see more data on some of these novel anti-estrogen agents that are moving through the various clinical pipelines. As it relates to some of our work, it's always interesting to see new emerging insights related to genomic predictors of response and resistance to CDK inhibitors and antiestrogens.

0:27 | In the broader breast cancer field in general, there's lots of other exciting areas that are upcoming, including the use of antibody drug conjugates in areas that we haven't yet had experience using. For example, in hormone receptor-positive disease as well as in HER2-low or negative disease. We are going to learn a lot more about that over the course of the next year, both in patient populations as well as in the translational and preclinical space.